Dagmara Szkolnicka, Ph.D., Co-founder and Chief Scientific Officer

April 9 | 1:30pm | Salone dei Cavalieri, Section 2

Copenhagen, Denmark


The company is developing a scalable and effective treatment for liver diseases using liver tissue implants developed from pluripotent stem cells (PSCs). Stimuliver has developed revolutionary proof-of-concept data which demonstrates that human liver tissue can be administered under the skin, providing long-term host liver support. For chronic liver disease patients, there are benefits of implanting cells subcutaneously, as the liver is highly inflamed making it a hostile environment for cell-based therapies. By utilizing PSCs as a source of tissue, the technology Stimuliver has developed is not dependent on donor organ availability. This may in the future provide a treatment which is available without waiting time and has the potential to reverse liver disease and prevent prolonged or recurrent hospitalizations. The research is based on technology developed at the University of Edinburgh’s Centre of Regenerative Medicine, is incubated at the BioInnovation Institute and was funded by the Novo Nordisk Foundation.

By using this website you agree to accept our Privacy Policy and Terms & Conditions